로딩 중…
지수 로딩 중…
Dianthus Therapeutics, Inc.
DNTH· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$106.02-0.84%
2026-08-03
Financials
Valuation Metrics
Dianthus Therapeutics, Inc.'s Market Cap is $5.80B. At end of 2025 it was $1.56B. Ranked #1293 of 3,112 in US market (top 42%), #435 of 1,445 on NASDAQ (top 30%), #72 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 27%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $5.80B | US#1,293/3,112 Sec#72/269 |
| Revenue | $1M | US#2,960/3,112 Sec#198/269 |
| Net Income | $-11M | US—/3,112 Sec—/269 |
| Total Assets | $1.25B | US#2,343/3,112 Sec#84/269 |
| Net Assets | $1.20B | US#1,649/3,112 Sec#56/269 |
| Value | ||
| P/B | 4.82x | US#2,142/3,112 Sec#137/269 |
| P/S | 2846.62x | US#2,957/3,112 Sec#202/269 |
| FCF Yield | -2.25% | US—/3,112 Sec—/269 |
| Profitability | ||
| ROE | -0.94% | US#2,193/3,112 Sec#75/269 |
| ROA | -0.91% | US#2,301/3,112 Sec#80/269 |
| Op. Margin | -14318.04% | US#2,961/3,112 Sec#198/269 |
| Revenue Growth | -60.19% | US#2,892/3,112 Sec#167/269 |
| Financial Health | ||
| Debt Ratio | 3.79% | US#33/3,112 Sec#10/269 |
| Total Debt | $1M | US#2,921/3,112 Sec#241/269 |
| FCF | $-130M | US#2,645/3,112 Sec#175/269 |
| Cash | $628M | US#931/3,112 Sec#45/269 |
| Current Ratio | 29.25x | US#84/3,112 Sec#11/269 |
| Performance | ||
| 1Y Return | 414.91% | US#27/3,112 Sec#14/269 |
| 1M Return | 12.38% | US#396/3,112 Sec#16/269 |
| From 52W High | -7.45% | US#804/3,112 Sec#34/269 |
| 1Y MDD | -20.20% | US#693/3,112 Sec#27/269 |
| Trading | ||
| Volume | 772,470 shares | US#1,716/3,112 Sec#166/269 |
| Trading Value | $81M | US#1,042/3,112 Sec#61/269 |
| Per Share | ||
| BPS | $13.05 | US#1,593/3,112 Sec#50/269 |